FDA approved drugs:
(show all 49)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Alimta
18
49
|
PEMETREXED (also Pemetrexed Disodium) |
Eli Lilly |
February 2004 |
Disease/s that Drug Treats:Mesothelioma
Indications and Usage:
18
ALIMTA® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:
16
1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:
18
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.
|
| 2 |
|
Aloxi
18
49
|
PALONOSETRON (hydrochloride) |
MGI Pharma, Helsinn Healthcare |
August 2003 |
Disease/s that Drug Treats:Chemotherapy side effects
Indications and Usage:
18
ALOXI is a serotonin-3 (5-HT3) receptor antagonist indicated in adults for: Moderately emetogenic cancer chemotherapy -- prevention ofacute and delayed nausea and vomiting associated with initial andrepeat courses (1.1) Highly emetogenic cancer chemotherapy -- prevention of acutenausea and vomiting associated with initial and repeat courses(1.1) Prevention of postoperative nausea and vomiting (PONV) for upto 24 hours following surgery. Efficacy beyond 24 hours has notbeen demonstrated (1.3)ALOXI is indicated in pediatric patients aged 1 month to less than 17 yearsfor: Prevention of acute nausea and vomiting associated with initialand repeat courses of emetogenic cancer chemotherapy, includinghighly emetogenic cancer chemotherapy (1.2)
DrugBank Targets:
16
5-hydroxytryptamine receptor 3A
Mechanism of Action:
18
Target: serotonin subtype 3 (5-HT3) receptor/ ion channels involved in ventricular polarization
Action: antagonist/ blocker
FDA: Palonosetron is a 5-HT3 receptor antagonist with a strong bindingaffinity for this receptor and little or no affinity for other receptors.Cancer chemotherapy may be associated with a high incidence ofnausea and vomiting, particularly when certain agents, such as cisplatin, areused. 5-HT3 receptors are located on the nerve terminals of the vagus in theperiphery and centrally in the chemoreceptor trigger zone of the areapostrema. It is thought that chemotherapeutic agents produce nausea andvomiting by releasing serotonin from the enterochromaffin cells of the smallintestine and that the released serotonin then activates 5-HT3 receptorslocated on vagal afferents to initiate the vomiting reflex.Postoperative nausea and vomiting is influenced by multiple patient,surgical and anesthesia related factors and is triggered by release of 5-HT ina cascade of neuronal events involving both the central nervous system andthe gastrointestinal tract. The 5-HT3 receptor has been demonstrated toselectively participate in the emetic response.
|
| 3 |
|
Anexsia
18
|
ACETAMINOPHEN; HYDROCODONE BITARTRATE |
Mallinckrodt Group |
August 1996 |
Disease/s that Drug Treats:chronic pain
Indications and Usage:
18
DrugBank Targets:
16
1. Prostaglandin G/H synthase 2;2. Prostaglandin G/H synthase 1;3. Prostaglandin G/H synthase 3;4. Mu-type opioid receptor;5. Delta-type opioid receptor
Mechanism of Action:
18
Target: cyclooxygenase (COX); OP1, OP2, and OP3 opiate receptors
Action: inhibitor; agonist
FDA: -
|
| 4 |
|
Arimidex
18
49
|
ANASTROZOLE |
AstraZeneca |
January 1996 |
Disease/s that Drug Treats:post menopausal breast cancer
Indications and Usage:
18
ARIMIDEX is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women withhormone receptor-positive early breast cancer (1.1) First-line treatment of postmenopausal women withhormone receptor-positive or hormone receptor unknownlocally advanced or metastatic breast cancer (1.2) Treatment of advanced breast cancer in postmenopausalwomen with disease progression following tamoxifentherapy. Patients with ER-negative disease and patientswho did not respond to previous tamoxifen therapy rarelyresponded to ARIMIDEX (1.3)
DrugBank Targets:
16
Cytochrome P450 19A1
Mechanism of Action:
18
Target: oral aromatase
Action: inhibitor
FDA: The growth of many cancers of the breast is stimulated or maintained by estrogens.In postmenopausal women, estrogens are mainly derived from the action of the aromataseenzyme, which converts adrenal androgens (primarily androstenedione and testosterone) toestrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and inthe cancer tissue itself can therefore be achieved by specifically inhibiting the aromataseenzyme.Anastrozole is a selective non-steroidal aromatase inhibitor. It significantly lowers serumestradiol concentrations and has no detectable effect on formation of adrenal corticosteroidsor aldosterone.
|
| 5 |
|
Aromasin Tablets
18
49
|
EXEMESTANE |
Pharmacia & Upjohn |
October 21. 1999 |
Disease/s that Drug Treats:advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Indications and Usage:
18
AROMASIN is an aromatase inhibitor indicated for: Incidences of cardiac ischemic events (myocardial infarction, angina, adjuvant treatment of postmenopausal women with estrogen-receptor and myocardial ischemia) were AROMASIN 1.6%, tamoxifen 0.6%.positive early breast cancer who have received two to three years of Incidence of cardiac failure: AROMASIN 0.4%, tamoxifen 0.3% (6,tamoxifen and are switched to AROMASIN for completion of a total of 6.1).five consecutive years of adjuvant hormonal therapy (14.1). Advanced breast cancer: Most common adverse events were mild to treatment of advanced breast cancer in postmenopausal women whose moderate and included hot flushes (13% vs. 5%), nausea (9% vs. 5%),disease has progressed following tamoxifen therapy (14.2).
DrugBank Targets:
16
Cytochrome P450 19A1
Mechanism of Action:
18
Target: steroidal aromatase
Action: inactivator
FDA: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that convertsandrogens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarilyestradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausalwomen is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens(estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromataseinhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breastcancer.Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrateandrostenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that bindsirreversibly to the active site of the enzyme, causing its inactivation, an effect also known as âsuicide inhibition.âExemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has nodetectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on otherenzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibitingthe aromatase enzyme.
|
| 6 |
|
Eloxatin
18
49
|
OXALIPLATIN |
Sanofi-aventis |
August 2002 |
Disease/s that Drug Treats:Metastatic colon or rectum carcinomas that have recurred or progressed within six months folowing first-line treatment
Indications and Usage:
18
ELOXATIN is a platinum-based drug used in combination with infusional 5-fluorouracil /leucovorin, which is indicated for: adjuvant treatment of stage III colon cancer in patients who haveundergone complete resection of the primary tumor. (1) treatment of advanced colorectal cancer. (1)
DrugBank Targets:
16
1. DNA
Mechanism of Action:
18
Target: DNA replication and transcription
Action: inhibitor
FDA: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives viadisplacement of the labile oxalate ligand. Several transient reactive species are formed, includingmonoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both interandintrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions oftwo adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by anintervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription.Cytotoxicity is cell-cycle nonspecific.In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. Incombination with 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activitygreater than either compound alone in several tumor models [HT29 (colon), GR (mammary), andL1210 (leukemia)].
|
| 7 |
|
Eulexin
18
|
FLUTAMIDE |
Schering-Plough |
June 1996 |
Disease/s that Drug Treats:prostate cancer
Indications and Usage:
18
EULEXIN capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B2C and Stage D2 metastatic carcinoma of the prostate. Stage B2C Prostatic Carcinoma: Treatment with EUlEXIN an the goserelin acetate implant shouls start 8 weeks prior to initiating radiation therapy and continue during radiation therapy. Stage D2 Metastatic Carcinoma: To acheive benefit from treatment, EULEXIN Capsules should be initiated with the LHRH-agonist and continued until progression.
DrugBank Targets:
16
1. Androgen receptor;2. Aryl hydrocarbon receptor
Mechanism of Action:
18
Target: androgen uptake and/or nuclear binding of angrogen in target tissues
Action: inhibitor
FDA: In animal studies, flutamide demonstrates potent anti-angrogenic effects. It exerts an antiandrogenic action by inhibiting angrogen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, eg. castration. Elevations of plasma testosterone and estraidiol levels have been noted following flutamide administration.
|
| 8 |
|
Evista
18
49
|
RALOXIFENE HYDROCHLORIDE |
Eli Lilly |
September 2007 |
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:
18
EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:
16
1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:
18
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
|
| 9 |
|
Faslodex
18
49
|
FULVESTRANT |
AstraZeneca |
April 2002 |
Disease/s that Drug Treats:Hormone receptor positive metastatic breast cancer
Indications and Usage:
18
FASLODEX is an estrogen receptor antagonist indicated for the: Treatment of hormone receptor positive metastatic breast cancer inpostmenopausal women with disease progression followingantiestrogen therapy.
DrugBank Targets:
16
1. Estrogen receptor
Mechanism of Action:
18
Target: estrogen receptors on tumor cells
Action: antagonist
FDA: Many breast cancers have estrogen receptors (ER) and thegrowth of these tumors can be stimulated by estrogen.Fulvestrant is an estrogen receptor antagonist that binds to theestrogen receptor in a competitive manner with affinitycomparable to that of estradiol and downregulates the ERprotein in human breast cancer cells.In vitro studies demonstrated that fulvestrant is a reversibleinhibitor of the growth of tamoxifen-resistant, as well asestrogen-sensitive human breast cancer (MCF-7) cell lines. Inin vivo tumor studies, fulvestrant delayed the establishment oftumors from xenografts of human breast cancer MCF-7 cellsin nude mice. Fulvestrant inhibited the growth of establishedMCF-7 xenografts and of tamoxifen-resistant breast tumorxenografts.Fulvestrant showed no agonist-type effects in in vivouterotropic assays in immature or ovariectomized mice andrats. In in vivo studies in immature rats and ovariectomizedmonkeys, fulvestrant blocked the uterotrophic action ofestradiol. In postmenopausal women, the absence of changesin plasma concentrations of FSH and LH in response tofulvestrant treatment (250 mg monthly) suggests no peripheralsteroidal effects.
|
| 10 |
|
Femara
18
49
|
LETROZOLE |
Novartis |
January 2001 |
Disease/s that Drug Treats:Hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer
Indications and Usage:
18
Femara is an aromatase inhibitor indicated for: Adjuva nt treatment of postmenopausal women with hormone receptorpositive early brea st cancer (1.1) Extended adjuvant treatment of postmenopausal women with early brea stcancer who have received prior standard adju vant ta moxifen thera py (1.2) First a nd second-line treatment of postmenopausal women with hormonereceptor positive or unknown advanced breast cancer (1.3)
DrugBank Targets:
16
1. Cytochrome P450 19A1
Mechanism of Action:
18
Target: aromatase enzyme system
Action: inhibitor
FDA: The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breastcancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive orreceptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy,adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).These interventions lead to decreased tumor mass or delayed progression of tumor growth in somewomen.In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, whichconverts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. Thesuppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore beachieved by specifically inhibiting the aromatase enzyme.Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits theconversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole isas effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression ofestrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to anincrease in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effecton adrenal mineralocorticoid or glucocorticoid synthesis.Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of womenwith letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown tosignificantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroidhormones.
|
| 11 |
|
Folotyn
18
49
|
PRALATREXATE |
Allos Therapeutics |
September 2009 |
Disease/s that Drug Treats:peripheral T-cell lymphoma
Indications and Usage:
18
FOLOTYN is a folate analog metabolic inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is based on overall response rate. Clinical benefit such asimprovement in progression-free survival or overall survival has not beendemonstrated. (1)
DrugBank Targets:
16
1. Dihydrofolate reductase;2. Thymidylate synthase
Mechanism of Action:
18
Target: dihydrofolate reductase
Action: inhibitor
FDA: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also acompetitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition resultsin the depletion of thymidine and other biological molecules the synthesis of which depends on single carbontransfer.
|
| 12 |
|
Fusilev
18
|
LEVOLEUCOVORIN CALCIUM |
Spectrum Pharmaceuticals |
March of 2008 |
Disease/s that Drug Treats:rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate
Indications and Usage:
18
Fusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impairedmethotrexate elimination and of inadvertent overdosage of folic acidantagonists. Use in combination chemotherapy with 5-fluorouracil in the palliativetreatment of patients with advanced metastatic colorectal cancer.(1)Limitations of UseFusilev is not approved for pernicious anemia and megaloblastic anemias.Improper use may cause a hematologic remission while neurologicmanifestations continue to progress. (1.1)
DrugBank Targets:
16
1. Thymidylate synthase
Mechanism of Action:
18
Target: therapeutic and toxic effects of folic acidantagonists / therapeutic and toxic effects of fluoropyrimidines used in cancer therapy
Action: counteract/enhance
FDA: 12.1.1 Levoleucovorin effects during high-dose methotrexate therapyLevoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not requirereduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of âonecarbonâmoieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acidantagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.12.1.2 Levoleucovorin effects in combination with 5-fluorouracilLevoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to andinhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily convertedto another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylatesynthase and thereby enhances the inhibition of this enzyme.
|
| 13 |
|
Gilotrif
18
49
|
AFATINIB DIMALEATE |
Boehringer Ingelheim |
July 2013 |
Disease/s that Drug Treats:metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:
18
GILOTRIF is a kinase inhibitor indicated for the first-line treatment ofpatients with metastatic non-small cell lung cancer (NSCLC) whose tumorshave epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21(L858R) substitution mutations as detected by an FDA-approved test (1)Limitation of Use: Safety and efficacy of GILOTRIF have not beenestablished in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:
16
1. Epidermal growth factor receptor;2. Receptor tyrosine-protein kinase erbB-2;3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:
18
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) andirreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtypeEGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, inpatients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors eitheroverexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.
|
| 14 |
|
Jevtana
18
49
|
CABAZITAXEL |
sanofi aventis |
June 2010 |
Disease/s that Drug Treats:prostate cancer
Indications and Usage:
18
JEVTANA is a microtubule inhibitor indicated in combination withprednisone for treatment of patients with hormone-refractory metastaticprostate cancer previously treated with a docetaxel-containing treatmentregimen. (1)
DrugBank Targets:
16
1. Tubulin alpha-4A chain;2. Tubulin beta-1 chain
Mechanism of Action:
18
Target: microtubule
Action: inhibitor
FDA: Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assemblyinto microtubules while simultaneously inhibiting disassembly. This leads to the stabilization ofmicrotubules, which results in the inhibition of mitotic and interphase cellular functions.
|
| 15 |
|
Kytril
18
|
GRANISETRON HYDROCHLORIDE |
Roche/SmithKline Beecham |
June 2001/ November 1997 |
Disease/s that Drug Treats:nausea and vomiting associated with chemotherapy
Indications and Usage:
18
KYTRIL Injection is a serotonin-3 (5-HT3) receptor antagonist indicated for: Prevention of nausea and/or vomiting associated with initial and repeatcourses of emetogenic cancer therapy, including high-dose cisplatin. (1) Prevention and treatment of postoperative nausea and vomiting in adults.(1)--------------
DrugBank Targets:
16
1. 5-hydroxytryptamine receptor 3A
Mechanism of Action:
18
Target: 5-hydroxytryptamine3 (5-HT3) receptor
Action: antagonist
FDA: Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for otherserotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2- or beta-adrenoreceptors; fordopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in thechemoreceptor trigger zone of the area postrema. During chemotherapy-induced vomiting, mucosalenterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferentdischarge and may induce vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetronblocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferretanimal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomitingwithin 5 to 30 seconds.In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of aneffect on plasma prolactin or aldosterone concentrations has been found in other studies.KYTRIL Injection exhibited no effect on oro-cecal transit time in normal volunteers given a single intravenousinfusion of 50 mcg/kg or 200 mcg/kg. Single and multiple oral doses slowed colonic transit in normalvolunteers.
|
| 16 |
|
Miraluma Test
18
|
TECHNETIUM TC-99M SESTAMIBI KIT |
DuPont Merck Pharmaceutical Company |
May 1997 |
Disease/s that Drug Treats:breast imaging
Indications and Usage:
18
Breast Imaging: MIRALUMA, Kit for the Preparation of Technetium Tc99m Sestamibi for Injection, is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. MIRALUMA is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy.
DrugBank Targets:
-
Mechanism of Action:
18
Target: malignant cells
Action: accumulates
FDA: The mechanism of Tc99m Sestanibi localization in various types of breast tissue (e.g. beinign, inflammatory, malignant, fiborous) has not been established.
|
| 17 |
|
Nolvadex
18
49
|
TAMOXIFEN CITRATE |
AstraZeneca |
October 1998 |
Disease/s that Drug Treats:Breast Cancer
Indications and Usage:
18
Metastatic Breast Cancer:NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. Inpremenopausal women with metastatic breast cancer, NOLVADEX is an alternative tooophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumorsare estrogen receptor positive are more likely to benefit from NOLVADEX therapy.Adjuvant Treatment of Breast Cancer:NOLVADEX is indicated for the treatment of node-positive breast cancer in women followingtotal mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In someNOLVADEX adjuvant studies, most of the benefit to date has been in the subgroup with four ormore positive axillary nodes.NOLVADEX is indicated for the treatment of axillary node-negative breast cancer in womenfollowing total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation.The estrogen and progesterone receptor values may help to predict whether adjuvantNOLVADEX therapy is likely to be beneficial.NOLVADEX reduces the occurrence of contralateral breast cancer in patients receiving adjuvantNOLVADEX therapy for breast cancer.Ductal Carcinoma in Situ (DCIS):In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated toreduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of thelabel). The decision regarding therapy with NOLVADEX for the reduction in breast cancerincidence should be based upon an individual assessment of the benefits and risks ofNOLVADEX therapy.Current data from clinical trials support five years of adjuvant NOLVADEX therapy for patientswith breast cancer. Reduction in Breast Cancer Incidence in High Risk Women:NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk forbreast cancer. This effect was shown in a study of 5 years planned duration with a medianfollow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. Thelonger-term effects are not known. In this study, there was no impact of tamoxifen on overall orbreast cancer-related mortality (see BOXED WARNING at the beginning of the label).NOLVADEX is indicated only for high-risk women. âHigh riskâ is defined as women at least35 years of age with a 5-year predicted risk of breast cancer ⥠1.67%, as calculated by the GailModel.Examples of combinations of factors predicting a 5-year risk ⥠1.67% are:Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and ahistory of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of atleast one breast biopsy; or LCISAge 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at firstlive birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 oryounger; or One first degree relative with a history of breast cancer, and a personal history of a breastbiopsy showing atypical hyperplasia.Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 oryounger; or One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, age at menarche 11 or less and age at first live birth 20 or more.Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 orolder and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at firstlive birth 30 or more.Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benignbreast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first livebirth 20 or older.Age 60 or older and: 5-year predicted risk of breast cancer ⥠1.67%, as calculated by the Gail Model.For women whose risk factors are not described in the above examples, the Gail Model isnecessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a GailModel Risk Assessment Tool by dialing 1-800-544-2007.There are insufficient data available regarding the effect of NOLVADEX on breast cancerincidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specificrecommendations on the effectiveness of NOLVADEX in these patients.After an assessment of the risk of developing breast cancer, the decision regarding therapy withNOLVADEX for the reduction in breast cancer incidence should be based upon an individualassessment of the benefits and risks of NOLVADEX therapy. In the NSABP P-1 trial,NOLVADEX treatment lowered the risk of developing breast cancer during the follow-up periodof the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICALPHARMACOLOGY).
DrugBank Targets:
16
1. Estrogen receptor;2. Estrogen receptor beta;3. 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase;4. Protein kinase C
Mechanism of Action:
18
Target: estrogen receptors
Action: competitor with estraidiol
FDA: NOLVADEX is a nonsteroidal agent that has demonstrated potent antiestrogenic properties inanimal test systems. The antiestrogenic effects may be related to its ability to compete withestrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of ratmammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression ofalready established DMBA-induced tumors. In this rat model, tamoxifen appears to exert itsantitumor effects by binding the estrogen receptors.In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol forestrogen receptor protein.
|
| 18 |
|
Plenaxis
18
|
ABARELIX |
Praecis Pharmaceuticals |
December 2003 |
Disease/s that Drug Treats:Prostate Cancer
Indications and Usage:
18
Plenaxis⢠is indicated for the palliative treatment of men with advanced symptomaticprostate cancer, in whom LHRH agonist therapy is not appropriate and who refusesurgical castration, and have one or more of the following: (1) risk of neurologicalcompromise due to metastases, (2) ureteral or bladder outlet obstruction due to localencroachment or metastatic disease, or (3) severe bone pain from skeletal metastasespersisting on narcotic analgesia.
DrugBank Targets:
16
1. Gonadotropin-releasing hormone receptor
Mechanism of Action:
18
Target: GnRH receptors in the pituitary gland
Action: competitive blocker
FDA: -
|
| 19 |
|
Sancuso
18
|
GRANISETRON |
ProStrakan |
September 2008 |
Disease/s that Drug Treats:chemotherapy-induced nausea and vomiting
Indications and Usage:
18
Sancuso is a serotonin subtype 3 (5-HT3) receptor antagonist indicated for theprevention of nausea and vomiting in patients receiving moderately and/orhighly emetogenic chemotherapy for up to 5 consecutive days. (1)
DrugBank Targets:
16
1. 5-hydroxytryptamine receptor 3A
Mechanism of Action:
18
Target: 5-hydroxytryptamine3 (5-HT3) receptor
Action: agonist
FDA: Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinityfor other serotonin receptors, including 5-HT1, 5-HT1A, 5-HT1B/C, 5-HT2; for alpha1-, alpha2-, or betaadrenoreceptors;for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioidreceptors.Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrallyin the chemoreceptor trigger zone of the area postrema. During chemotherapy that inducesvomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. Thisevokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenicstimuli such as cisplatin. In the ferret animal model, a single granisetron injection preventedvomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.
|
| 20 |
|
Sensipar
18
|
CINACALCET HYDROCHLORIDE |
Amgen |
March 2004 |
Disease/s that Drug Treats:Hyperparathyroidism / Hypercalcemia
Indications and Usage:
18
Sensipar is a calcium-sensing receptor agonist indicated for: concentration time curve) is increased in patients with moderate and Secondary Hyperparathyroidism (HPT) in adult patients with chronic severe hepatic impairment. Patients should be closely monitored forkidney disease (CKD) on dialysis. (1.1) serum calcium, serum phosphorus, and iPTH levels throughout Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). (1.2) treatment. (5.3, 8.7) Hypercalcemia in adult patients with primary HPT for whomparathyroidectomy would be indicated on the basis of serum calciumlevels, but who are unable to undergo parathyroidectomy. (1.3)
DrugBank Targets:
16
1. Extracellular calcium-sensing receptor
Mechanism of Action:
18
Target: calcium-sensing receptor
Action: increases sensitivity to activation by extracellular calcium
FDA: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulatorof PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, directly lowers PTH levels byincreasing the sensitivity of the calcium-sensing receptor to extracellular calcium. The reduction in PTH isassociated with a concomitant decrease in serum calcium levels.
|
| 21 |
|
Sprycel
18
49
|
DASATINIB |
Bristol-Myers Squibb |
June 2006 |
Disease/s that Drug Treats:Chronic Myeloid Leukemia
Indications and Usage:
18
SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+)chronic myeloid leukemia (CML) in chronic phase. (1, 14) adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+CML with resistance or intolerance to prior therapy including imatinib. (1,14) adults with Philadelphia chromosome-positive acute lymphoblasticleukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14)
DrugBank Targets:
16
1. Tyrosine-protein kinase ABL1;2. Proto-oncogene tyrosine-protein kinase Src;3. Ephrin type-A receptor 2;4. Tyrosine-protein kinase Lck;5. Tyrosine-protein kinase Yes;6. Mast/stem cell growth factor receptor Kit;7. Platelet-derived growth factor receptor beta;8. Signal transducer and activator of transcription 5B;9. Abelson tyrosine-protein kinase 2;10. Tyrosine-protein kinase Fyn
Mechanism of Action:
18
Target: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ kinases
Action: inhibitor
FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family(SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib ispredicted to bind to multiple conformations of the ABL kinase.In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylatesensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia(CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under theconditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABLkinase domain mutations, activation of alternate signaling pathways involving the SRCfamily kinases (LYN, HCK), and multi-drug resistance gene overexpression.
|
| 22 |
|
Sylatron
18
49
|
PEGINTERFERON ALFA-2B |
Merck |
April 2011 |
Disease/s that Drug Treats:melanoma
Indications and Usage:
18
PegIntron is an antiviral indicated for treatment of Chronic Hepatitis C(CHC) in patients with compensated liver disease. (1.1)
DrugBank Targets:
16
1. Interferon alpha/beta receptor 1;2. Interferon alpha/beta receptor 2
Mechanism of Action:
18
Target: innate antiviral immune response
Action: inducer
FDA: Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response [see Microbiology (12.4)].
|
| 23 |
|
Synercid I.V.
18
|
DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN |
Rhone Poulenc Rorer |
September 1999 |
Disease/s that Drug Treats:For serious or life-threatening infections associated w/ vancomycin-resistant Enterococcus faecium (VREF) bacteremia.
Indications and Usage:
18
Synercid is indicated in adults for the treatment of the following infections when caused bysusceptible strains of the designated microorganisms.Complicated skin and skin structure infections caused by Staphylococcus aureus (methicillinsusceptible) or Streptococcus pyogenes. (See CLINICAL STUDIES.)
DrugBank Targets:
16
16
1. Streptogramin A acetyltransferase| 1. 23S rRNA;2. 50S ribosomal protein L10;3. 50S ribosomal protein L22
Mechanism of Action:
18
Target: bacterial ribosome - protien synthesis
Action: inhibitor
FDA: The site of action of quinupristin and dalfopristin is the bacterial ribosome. Dalfopristin has beenshown to inhibit the early phase of protein synthesis while quinupristin inhibits the late phase ofprotein synthesis. Synercid is bactericidal against isolates of methicillin-susceptible andmethicillin-resistant staphylococci. The mode of action of Synercid differs from that of otherclasses of antibacterial agents such as Ã-lactams, aminoglycosides, glycopeptides, quinolones,macrolides, lincosamides and tetracyclines. Therefore, there is no cross resistance betweenSynercid and these agents when tested by the minimum inhibitory concentration (MIC) method.
|
| 24 |
|
Torisel
18
49
|
TEMSIROLIMUS |
Wyeth |
May 2007 |
Disease/s that Drug Treats:renal cell carcinoma
Indications and Usage:
18
TORISEL® is a kinase inhibitor indicated for the treatment of advanced renalcell carcinoma. (1)
DrugBank Targets:
16
1. Serine/threonine-protein kinase mTOR
Mechanism of Action:
18
Target: mTOR
Action: inhibitor
FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. Inin vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.
|
| 25 |
|
Tykerb
18
49
|
LAPATINIB DITOSYLATE |
GlaxoSmithKline |
March 2007 |
Disease/s that Drug Treats:breast cancer
Indications and Usage:
18
TYKERB, a kinase inhibitor, is indicated in combination with: (1) capecitabine, for the treatment of patients with advanced or metastatic breastcancer whose tumors overexpress HER2 and who have received prior therapyincluding an anthracycline, a taxane, and trastuzumab.Limitation of Use: Patients should have disease progression on trastuzumabprior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptorpositivemetastatic breast cancer that overexpresses the HER2 receptor forwhom hormonal therapy is indicated.TYKERB in combination with an aromatase inhibitor has not been comparedto a trastuzumab-containing chemotherapy regimen for the treatment ofmetastatic breast cancer.
DrugBank Targets:
16
1. Epidermal growth factor receptor;2. Receptor tyrosine-protein kinase erbB-2
Mechanism of Action:
18
Target: Epidermal Growth Factor Receptor (EGFR [ErbB1]), Human Epidermal Receptor Type 2 (HER-2 [ErbB2]) receptor
Action: inhibitor intracellular tyrosine kinase domains
FDA: Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinasedomains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human EpidermalReceptor Type 2 (HER2 [ErbB2]) receptors (estimated Kiapp values of 3nM and 13nM,respectively) with a dissociation half-life of ï³300 minutes. Lapatinib inhibits ErbB-driven tumorcell growth in vitro and in various animal models.An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (theactive metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. Thegrowth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines.Lapatinib retained significant activity against breast cancer cell lines selected for long-termgrowth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-crossresistancebetween these two agents.Hormone receptor-positive breast cancer cells (with ER [Estrogen Receptor] and/or PgR[Progesterone Receptor]) that coexpress the HER2 tend to be resistant to established endocrinetherapies. Similarly, hormone receptor-positive breast cancer cells that initially lack EGFR orHER2 upregulate these receptor proteins as the tumor becomes resistant to endocrine therapy.
|
| 26 |
|
UroXatral
18
|
ALFUZOSIN HYDROCHLORIDE |
Sanofi-aventis |
June 2003 |
Disease/s that Drug Treats:Benign Prostatic Hyperplasia
Indications and Usage:
18
UROXATRAL is an alpha adrenergic antagonist, indicated for thetreatment of signs and symptoms of benign prostatic hyperplasia. (1)Important Limitations of Use:UROXATRAL is not indicated for treatment of hypertension. (1.1)UROXATRAL is not indicated for use in the pediatric population. (1.1,8.4, 12.3)
DrugBank Targets:
16
1. Alpha-1A adrenergic receptor;2. Alpha-1B adrenergic receptor;3. Alpha-1D adrenergic receptor;4. Potassium voltage-gated channel subfamily H member 2
Mechanism of Action:
18
Target: post-synaptic alpha1-adrenoreceptors
Action: selective antagonist
FDA: Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located inthe prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
|
| 27 |
|
Xtandi
18
49
|
ENZALUTAMIDE |
Medivation |
August 2012 |
Disease/s that Drug Treats:metastatic castration-resistant prostate cancer
Indications and Usage:
18
XTANDI is an androgen receptor inhibitor indicated for the treatment ofpatients with metastatic castration-resistant prostate cancer. (1)
DrugBank Targets:
16
1. Androgen receptor
Mechanism of Action:
18
Target: androgen receptor
Action: inhibitor
FDA: Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptorsignaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgenreceptors and inhibit androgen receptor nuclear translocation and interaction with DNA. A majormetabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamidedecreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumorvolume in a mouse prostate cancer xenograft model.
|
| 28 |
|
Zaltrap
18
49
|
ZIV-AFLIBERCEPT |
Sanofi-aventis |
August 2012 |
Disease/s that Drug Treats:metastatic colorectal cancer
Indications and Usage:
18
ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan- (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC)that is resistant to or has progressed following an oxaliplatin-containingregimen. (1)
DrugBank Targets:
16
1. Vascular endothelial growth factor A;2. Placenta growth factor;3. Vascular endothelial growth factor B
Mechanism of Action:
18
Target: VEGF-A, VEGF-B, PlGF
Action: inhibitor of binding and activation of their cognate receptors
FDA: Ziv-aflibercept acts as a soluble receptor that binds to human VEGF-A (equilibrium dissociationconstant KD of 0.5 pM for VEGF-A165 and 0.36 pM for VEGF-A121), to human VEGF-B (KD of1.92 pM), and to human PlGF (KD of 39 pM for PlGF-2). By binding to these endogenousligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. Thisinhibition can result in decreased neovascularization and decreased vascular permeability.In animals, ziv-aflibercept was shown to inhibit the proliferation of endothelial cells, therebyinhibiting the growth of new blood vessels. Ziv-aflibercept inhibited the growth ofxenotransplanted colon tumors in mice.
|
| 29 |
|
Zoladex
18
49
|
GOSERELIN ACETATE |
AstraZeneca |
January 1996 |
Disease/s that Drug Treats:prostate cancer
Indications and Usage:
18
ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicatedfor: Use in combination with flutamide for the management of locally confinedcarcinoma of the prostate (1.1) Palliative treatment of advanced carcinoma of the prostate (1.2) The management of endometriosis (1.3) Use as an endometrial-thinning agent prior to endometrial ablation fordysfunctional uterine bleeding (1.4) Use in the palliative treatment of advanced breast cancer in pre- andperimenopausal women (1.5)
DrugBank Targets:
16
1. Lutropin-choriogonadotropic hormone receptor;2. Gonadotropin-releasing hormone receptor
Mechanism of Action:
18
Target: pituitary gonadotropinsecretion
Action: inhibitor
FDA: ZOLADEX is a synthetic decapeptide analogue of GnRH. ZOLADEX acts as an inhibitor of pituitary gonadotropinsecretion when administered in the biodegradable formulation. In animal and in vitro studies, administration of goserelinresulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-inducedrat mammary tumor and Dunning R3327 prostate tumor.
|
| 30 |
|
Aldurazyme
18
|
LARONIDASE |
Genzyme |
May 2003 |
Disease/s that Drug Treats:Mucopolysaccharidosis I
Indications and Usage:
18
ALDURAZYME is a hydrolytic lysosomal glycosaminoglycan (GAG)- specific enzyme indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. ALDURAZYME has been shown to improve pulmonary function and walking capacity. ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder (1).
DrugBank Targets:
16
Iduronic acid
Mechanism of Action:
18
Target: α-L-iduronidase
Action: replacement
FDA: Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis I (MPS I) is characterized by the deficiency of ï¡-L-iduronidase, a lysosomal hydrolase which catalyzes the hydrolysis of terminal ï¡-L-iduronic acid residues of dermatan sulfate and heparan sulfate. Reduced or absent ï¡-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction. The rationale of ALDURAZYME therapy in MPS I is to provide exogenous enzyme for uptake into lysosomes and increase the catabolism of GAG. ALDURAZYME uptake by cells into lysosomes is most likely mediatedby the mannose-6-phosphate-terminated oligosaccharide chains of laronidase binding to specific mannose-6- phosphate receptors. Because many proteins in the blood are restricted from entry into the central nervous system (CNS) by the blood brain barrier, effects of intravenously administered ALDURAZYME on cells within the CNS cannot be inferred from activity in sites outside the CNS. The ability of ALDURAZYME to cross the blood brain barrier has not been evaluated in animal models or in clinical studies.
|
| 31 |
|
Allegra
18
|
FEXOFENADINE HYDROCHLORIDE |
Hoechst Marion Roussel |
July 1996 |
Disease/s that Drug Treats:seasonal allergic rhinitis
Indications and Usage:
18
Seasonal Allergic Rhinitis ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria ALLEGRA is indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. It significantly reduces pruritus and the number of wheals.
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: Fexofenadine hydrochloride is an antihistamine with selective peripheral H1-receptor antagonist activity. Both enantiomers of fexofenadine hydrochloride displayed approximately equipotent antihistaminic effects. Fexofenadine inhibited histamine release from peritoneal mast cells in rats. In laboratory animals, no anticholinergic, alpha1-adrenergic or beta-adrenergic-receptor blocking effects were observed. No sedative or other central nervous system effects were observed. Radiolabeled tissue distribution studies in rats indicated that fexofenadine does not cross the blood-brain barrier.
|
| 32 |
|
Arnuity Ellipta
18
|
FLUTICASONE FUROATE |
GlaxoSmithKline |
August 2014 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
DrugBank Targets:
16
Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: anti-inflamatory
FDA: -
|
| 33 |
|
Augmentin
18
|
AMOXICILLIN; CLAVULANATE POTASSIUM |
SmithKline Beecham |
February 1996 |
Disease/s that Drug Treats:sinusitis, bronchitis, pneumonia
Indications and Usage:
18
AUGMENTIN is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for treatment of the following: Lower respiratory tract infections (1.1) Acute bacterial otitis media (1.2) Sinusitis (1.3) Skin and skin structure infections (1.4) Urinary tract infections (1.5)
DrugBank Targets:
16
16
Beta-lactamase|Penicillin-binding protein 1A
Mechanism of Action:
18
Target: -
Action: -
FDA: AUGMENTIN is an antibacterial drug. [see Microbiology 12.4]. Amoxicillin is a semisynthetic antibiotic with in vitro bactericidal activity against Grampositive and Gram-negative bacteria. Amoxicillin is, however, susceptible to degradation by beta-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a beta-lactam, structurally related to the penicillins, which possesses the ability to inactivate some beta-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated beta-lactamases frequently responsible for transferred drug resistance. The formulation of amoxicillin and clavulanic acid in AUGMENTIN protects amoxicillin from degradation by some beta-lactamase enzymes and extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin. Amoxicillin/clavulanic acid has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
|
| 34 |
|
Avelox I.V.
18
|
MOXIFLOXACIN HYDROCHLORIDE |
Bayer |
November 2001 |
Disease/s that Drug Treats:Susceptible strains of sinusitis, bronchitis, pneumonia, skin structure infections
Indications and Usage:
18
AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: * Acute Bacterial Sinusitis (1.1) * Acute Bacterial Exacerbation of Chronic Bronchitis (1.2) * Community Acquired Pneumonia (1.3) * Skin and Skin Structure Infections: Uncomplicated (1.4) and Complicated (1.5) * Complicated Intra-Abdominal Infections (1.6) * Plague (1.7) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (1.8)
DrugBank Targets:
16
DNA gyrase subunit A|DNA topoisomerase 4 subunit A|DNA topoisomerase 2-alpha
Mechanism of Action:
18
Target: topoisomerase II (DNA gyrase) and topoisomerase IV
Action: inhibitpr
FDA: AVELOX is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4)]. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination.
|
| 35 |
|
Cayston
18
|
AZTREONAM |
Gilead |
February 2010 |
Disease/s that Drug Treats:cystic fibrosis patients with Pseudomonas aeruginosa
Indications and Usage:
18
CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia. (1)
DrugBank Targets:
16
Penicillin-binding protein 3|Beta-lactamase
Mechanism of Action:
18
Target: penicillin binding proteins of susceptible bacteria
Action: inhibition of bacterial cell wall synthesis
FDA: Aztreonam is an antibacterial drug [see Clinical Pharmacology (12.4)]. Aztreonam exhibits activity in vitro against Gram-negative aerobic pathogens including P. aeruginosa. Aztreonam binds to penicillinbinding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis and death of the cell. Aztreonam activity is not decreased in the presence of CF lung secretions.
|
| 36 |
|
Cedax
18
|
CEFTIBUTEN DIHYDRATE |
Schering-Plough |
December 1995 |
Disease/s that Drug Treats:chronic bronchitis, infection of the middle ear, pharyngitis/tonsillitis
Indications and Usage:
18
CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamaseproducing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control. Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes. NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered. Pharyngitis and Tonsillitis due to Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from the oropharynx; however, data establishing the efficacy of the CEDAX product for the prophylaxis of subsequent rheumatic fever are not available.
DrugBank Targets:
16
Peptidoglycan synthase FtsI|Penicillin-binding protein 1A|Penicillin-binding protein 1B|Penicillin-binding protein 2
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 37 |
|
Clarinex
18
|
DESLORATADINE |
Schering-Plough |
February 2002 |
Disease/s that Drug Treats:Allergic rhinitis; Chronic ideopathic urticaria
Indications and Usage:
18
CLARINEX is an H1-receptor antagonist indicated for: * Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. (1.1) * Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. (1.2) * Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older. (1.3)
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: histamine
Action: long-acting tricyclic antagonist
FDA: Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2-3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H1-receptor. Desloratadine inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.
|
| 38 |
|
Claritin-D 24 Hour Extended Release Tablets
18
|
LORATADINE; PSEUDOEPHEDRINE SULFATE |
Schering-Plough |
August 1996 |
Disease/s that Drug Treats:nasal congestion
Indications and Usage:
18
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 39 |
|
DuoNeb
18
|
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE |
Dey Laboratories |
March 2001 |
Disease/s that Drug Treats:Bronchospasm associated with COPD for patients who require more than one bronchodilator
Indications and Usage:
18
DuoNeb® - (Ipratropium Bromide 0.5 mg/Albuterol Sulfate 3.0 mg*) - Inhalation Solution - *Equivalent to 2.5 mg albuterol base - DESCRIPTION - The active components in DuoNeb® Inhalation Solution are albuterol sulfate and ipratropium bromide. Albuterol sulfate, is a salt of racemic albuterol and a relatively selective β2-adrenergic bronchodilator chemically described as α1-[(tert-butylamino)methyl]-4-hydroxy-mxylene-α, α'-diol sulfate (2:1) (salt). It has a molecular weight of 576.7 and the empirical formula is (C13H21NO3)2*H2SO4. It is a white crystalline powder, soluble in water and slightly soluble in ethanol. The World Health Organization recommended name for albuterol base is salbutamol.Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8- azoniabicyclo [3.2.1]-octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8methyl-8-(1- methylethyl)-, bromide, monohydrate (endo, syn)-, (±)-; a synthetic quaternary ammonium compound, chemically related to atropine. It has a molecular weight of 430.4 and the empirical formula is C20H30BrNO3*H2O. It is a white crystalline substance, freely soluble in water and lower alcohols, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons.
DrugBank Targets:
16
16
Muscarinic acetylcholine receptor M1|Muscarinic acetylcholine receptor M2|Muscarinic acetylcholine receptor M3|Beta-2 adrenergic receptor|Beta-1 adrenergic receptor
Mechanism of Action:
18
Target: beta2-adrenergic|acetylcholine
Action: bronchodilator|blocker of physiologic action
FDA: -
|
| 40 |
|
Dymista
18
|
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE |
Meda Pharmaceuticals Inc |
May 2012 |
Disease/s that Drug Treats:seasonal allergic rhinitis
Indications and Usage:
18
DYMISTA contains an H1-receptor antagonist and a corticosteroid, and is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief. (1.1)
DrugBank Targets:
16
16
Histamine H1 receptor|Glucocorticoid receptor|Progesterone receptor|Cytosolic phospholipase A2|Mineralocorticoid receptor|
Mechanism of Action:
18
Target: histamine H1-receptor
Action: antagonist|anti-inflammatory
FDA: DYMISTA: DYMISTA contains both azelastine hydrochloride and fluticasone propionate; therefore, the mechanisms of actions described below for the individual components apply to DYMISTA. These drugs represent two different classes of medications (histamine H1-receptor antagonist and synthetic corticosteroid). Azelastine hydrochloride: Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H1-receptor antagonist activity in isolated tissues, animal models, and humans. Azelastine hydrochloride in DYMISTA is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in vitro studies. The major metabolite, desmethylazelastine, also possesses H1-receptor antagonist activity. Fluticasone propionate: Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. In vitro dose response studies on a cloned human glucocorticoid receptor system involving binding and gene expression afforded 50% responses at 1.25 and 0.17 nM concentrations, respectively. Fluticasone propionate was 3-fold to 5-fold more potent than dexamethasone in these assays. Data from the McKenzie vasoconstrictor assay in man also support its potent glucocorticoid activity. The clinical relevance of these findings is unknown. The precise mechanism through which fluticasone propionate affects allergic rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation.
|
| 41 |
|
Invanz
18
|
ERTAPENEM SODIUM |
Merck |
November 2001 |
Disease/s that Drug Treats:Bacterial infections
Indications and Usage:
18
INVANZ is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: * Complicated intra-abdominal infections. (1.1) * Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. (1.2) * Community-acquired pneumonia. (1.3) * Complicated urinary tract infections including pyelonephritis. (1.4) * Acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections. (1.5) INVANZ is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. (1.6)
DrugBank Targets:
16
Penicillin-binding protein 2|Penicillin-binding protein 2|Peptidoglycan synthase FtsI|Peptidoglycan synthase FtsI|D-alanyl-D-alanine carboxypeptidase DacB|Penicillin-binding protein 1A|Penicillin-binding protein 1B|D-alanyl-D-alanine carboxypeptidase DacC
Mechanism of Action:
18
Target: bacterial cell walls
Action: blocks formation
FDA: Ertapenem sodium is a carbapenem antibiotic [see Clinical Pharmacology (12.4)]. Mechanism of Action Ertapenem has in vitro activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Mechanism of Resistance Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-betalactamases.
|
| 42 |
|
Oralair
18
|
|
Greer Labs |
April 2014 |
Disease/s that Drug Treats:grass pollen-induced allergic rhinitis with or without conjunctivitis
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 43 |
|
Patanase
18
|
OLOPATADINE HYDROCHLORIDE |
Alcon |
April 2008 |
Disease/s that Drug Treats:seasonal allergic rhinitis
Indications and Usage:
18
PATANASE Nasal Spray is an H1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older. (1)
DrugBank Targets:
16
Histamine H1 receptor|Protein S100-A1|Protein S100-A12|Protein S100-B|Protein S100-A13|Protein S100-A2
Mechanism of Action:
18
Target: H1 -receptor
Action: selective antagonist
FDA: Olopatadine is a histamine H1 -receptor antagonist. The antihistaminic activity of olopatadine has been documented in isolated tissues, animal models, and humans.
|
| 44 |
|
Rhinocort Aqua Nasal Spray
18
|
BUDESONIDE |
AstraZeneca |
October 1999 |
Disease/s that Drug Treats:Management of nasal symptoms of seasonal or perennial allergic rhinitis in adults and children six years of age or older
Indications and Usage:
18
DrugBank Targets:
16
Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: -
|
| 45 |
|
Tygacil
18
|
TIGECYCLINE |
Wyeth |
2005 |
Disease/s that Drug Treats:complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia
Indications and Usage:
18
TYGACIL is a tetracycline class antibacterial indicated in patients 18 years of age and older for: * Complicated skin and skin structure infections (1.1) * Complicated intra-abdominal infections (1.2) * Community-acquired bacterial pneumonia (1.3) Limitations of Use: TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilatorassociated pneumonia (1.4). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.
DrugBank Targets:
16
16S rRNA|30S ribosomal protein S9|30S ribosomal protein S12|30S ribosomal protein S13|30S ribosomal protein S14|30S ribosomal protein S19
Mechanism of Action:
18
Target: 30S ribosomal subunit
Action: inhibits protein translation
FDA: Tigecycline is a tetracycline class antibacterial [see Microbiology (12.4)]. Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic; however, TYGACIL has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila.
|
| 46 |
|
Xolair
18
|
OMALIZUMAB |
Genentech |
June 2003 |
Disease/s that Drug Treats:asthma
Indications and Usage:
18
Xolair is an anti-IgE antibody indicated for: * Moderate to severe persistent asthma in patients (12 years of age and above) with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids (1.1) * Chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H1 antihistamine treatment (1.2) Limitations of use: * Not indicated for other allergic conditions or other forms of urticaria. (1.1, 1.2,) * Not indicated for acute bronchospasm or status asthmaticus. (1.1, 5.3)
DrugBank Targets:
16
High affinity immunoglobulin epsilon receptor subunit alpha|High affinity immunoglobulin epsilon receptor subunit beta
Mechanism of Action:
18
Target: the binding of IgE to the high-affinity IgE receptor (Fc&RI)
Action: inhibitor
FDA: Asthma Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FcεRI-bearing cells limits the degree of release of mediators of the allergic response. Treatment with Xolair also reduces the number of FcεRI receptors on basophils in atopic patients. Chronic Idiopathic Urticaria Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FcεRI) on cells down-regulate. The mechanism by which these effects of omalizumab result in an improvement of CIU symptoms is unknown.
|
| 47 |
|
Xyzal
18
|
LEVOCETIRIZINE DIHYDROCHLORIDE |
UCB |
May 2007 |
Disease/s that Drug Treats:seasonal and perennial allergic rhinitis and urticaria
Indications and Usage:
18
XYZAL is a histamine H1-receptor antagonist indicated for: * The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) * The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3)
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: H1-receptor
Action: selective antagonist
FDA: Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). The clinical relevance of this finding is unknown.
|
| 48 |
|
Zosyn
18
|
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM |
Wyeth |
May 1996 |
Disease/s that Drug Treats:pneumonia
Indications and Usage:
18
ZOSYN is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: * Intra-abdominal infections (1.1) * Skin and skin structure infections (1.2) * Female pelvic infections (1.3) * Community-acquired pneumonia (1.4) * Nosocomial pneumonia (1.5)
DrugBank Targets:
16
16
Beta-lactamase SHV-1|Beta-lactamase TEM|Penicillin-binding protein 3|Penicillin-binding protein 2B|Penicillin-binding protein 2a|Penicillin-binding protein 1b
Mechanism of Action:
18
Target: -
Action: -
FDA: ZOSYN is an antibacterial drug [see Microbiology (12.4)].Mechanism of Action Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. In vitro, piperacillin is active against a variety of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins. It is, however, a β-lactamase inhibitor of the Molecular class A enzymes, including RichmondSykes class III (Bush class 2b & 2b') penicillinases and cephalosporinases. It varies in its ability to inhibit class II and IV (2a & 4) penicillinases. Tazobactam does not induce chromosomallymediated β-lactamases at tazobactam concentrations achieved with the recommended dosage regimen.
|
| 49 |
|
Zyrtec
18
|
CETIRIZINE HYDROCHLORIDE |
Pfizer |
December 1995 |
Disease/s that Drug Treats:allergy
Indications and Usage:
18
ZYRTEC-D 12 HOUR Extended Release Tablets should be administered when both the antihistaminic properties of cetirizine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired. ZYRTEC-D 12 HOUR Extended Release Tablets are indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. In clinical studies, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies have shown no measurable affinity for other than H1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered cetirizine does not significantly occupy cerebral H1 receptors.
|
Drugs for Myeloproliferative Syndrome, Transient (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 53)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Phase 3 |
|
50-03-3 |
|
|
Synonyms:
21-O-acetylcortisol
Cortisol 21-acetate
|
Hydrocortisone 21-acetate
|
|
| 2 |
|
leucovorin |
Approved |
Phase 3,Phase 2 |
|
58-05-9 |
6006
143
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
folinate
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 3 |
|
Cytarabine |
Approved, Investigational |
Phase 3 |
|
147-94-4 |
6253
|
|
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
147-94-4
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-β-D-arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-amino-1-b-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-b-D-Arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-amino-1-beta-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-beta-D-Arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
Alexan
AR3
Arabinocytidine
Arabinofuranosylcytosine
Arabinoside, cytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
AraC
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Aracytidine
Ara-Cytidine
Aracytin
Aracytine
Arafcyt
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
beta-Ara C
beta-Arabinosylcytosine
beta-Cytosine arabinoside
Beta-cytosine arabinoside
beta-D-Arabinosylcytosine
BIDD:GT0371
BIDD:PXR0139
BTB15125
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
Citarabina
|
Citarabina [INN-Spanish]
CPD000449317
Cytarabin
Cytarabina
cytarabine
Cytarabine (JP15/USP/INN)
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine hydrochloride
cytarabine liposome injection
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
D00168
DB00987
Depocyt
Depocyt (liposomal)
Depocyt (TN)
Depocyte
DepoCyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Hydrochloride, cytarabine
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
Lopac0_000316
LS-860
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
Spongocytidine
SR-01000075773-3
Tarabine
TL8001048
U 19920A
U-19,920
U-19920
Udicil
UNII-04079A1RDZ
ZINC03795098
|
|
| 4 |
|
Methotrexate |
Approved |
Phase 3,Phase 2 |
|
59-05-2, 1959-05-2 |
126941
|
|
Synonyms:
4-amino-10-Methylfolate
4-amino-10-methylfolic acid
4-amino-10-Methylfolic acid
4-amino-N(10)-Methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
|
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Rheumatrex
Sodium, methotrexate
Trexall
|
|
| 5 |
|
Hydrocortisone |
Approved, Vet_approved |
Phase 3 |
|
50-23-7 |
5754
|
|
Synonyms:
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
[3H]cortisol
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-hydrocortisone
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11β,17α,21-trihydroxy-4-pregnene-3,20-dione
11β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
2v95
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-pregnen-11β,17α,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
AI3-25006
AKOS001582651
Alacort
Ala-cort
Ala-Cort
Ala-scalp
Ala-Scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Anusol-HC
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
Balneol-hc
Balneol-HC
Barseb HC
Basan-corti
Basan-Corti
Beta-hc
Beta-HC
b-HC
Bio-0648
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
C00735
C21H30O5
CaldeCORT spray
CaldeCORT Spray
CCRIS 5854
Cetacort
CHEBI:17650
CHEMBL389621
Chronocort
CID5754
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
Compound F
Compound F (kendall)
Corhydron
Cor-oticin
COR-OTICIN
Cortanal
Cor-tar-quin
Cort-dome
Cort-Dome
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin otico
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
Cortril
CORTRIL
CPD000653523
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Dermacort
Derm-aid
Derm-Aid
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
Ef corlin
Efcorbin
Efcortelan
Efcortelin
EINECS 200-020-1
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EU-0100594
Evacort
Ficortril
Fiocortril
Flexicort
Foille insetti
Foille Insetti
Genacort
Genacort (lotion)
Glycort
gyno-Cortisone
Gyno-Cortisone
H 4001
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
|
H4001_SIGMA
H6909_SIGMA
HC
HC #1
HC #4
HC (HYDROCORTISONE)
H-Cort
Heb cort
Heb Cort
Heb-cort
Heb-Cort
Hi-cor
Hidalone
hidro-Colisona
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
HMS1569I16
HMS2090M04
HSDB 3339
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
Hydro-Adreson
hydro-Colisona
Hydro-Colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
hydrocortisone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone acetate
Hydrocortisone alcohol
HYDROCORTISONE AND ACETIC ACID
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
HYDROCORTISONE IN ABSORBASE
Hydrocortisone sodium phosphate
Hydrocortisone solution
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
HYDROCORTONE
hydro-RX
Hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
LMST02030001
Locoid
Lopac0_000594
LS-7439
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
Milliderm
MLS000069609
MLS001148103
MLS002207135
MLS002222189
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
neo-Cort-dome
neo-Cortef
Neo-Cortef
Neosporin-H ear
Neosporin-H Ear
Nogenic HC
NSC 10483
NSC10483
NSC-10483
Nutracort
Nystaform-HC
Ophthocort
Optef
ORLEX HC
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
Otosone-F
Pediotic suspension
Pediotic Suspension
Penecort
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Preparation H Hydrocortisone Cream
Prepcort
Prestwick_265
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein's substance m
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
Sanatison
Scalp-Cort
Scalpicin capilar
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Systral Hydrocort
Tarcortin
Terra-cortril
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
U-cort
Uniderm
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Vioform-hydrocortisone
VoSol HC
Vytone
Zenoxone
β-HC
|
|
| 6 |
|
Thioguanine |
Approved |
Phase 3 |
|
154-42-7 |
2723601
|
|
Synonyms:
154-42-7
2 amino 6 Purinethiol
2 Amino 6 Purinethiol
2-amino 6MP
2-Amino 6MP
2-Amino-1,7-dihydro-6H-purin-6-thion
2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]
2-amino-1,7-dihydro-6H-Purine-6-thione
2-Amino-1,7-dihydro-6H-purine-6-thione
2-amino-1,9-dihydropurine-6-thione
2-amino-1,9-Dihydropurine-6-thione
2-amino-3,7-dihydropurine-6-thione
2-amino-6-Mercaptopurine
2-Amino-6-mercaptopurine
2-amino-6-Merkaptopurin
2-Amino-6-merkaptopurin
2-Amino-6-merkaptopurin [Czech]
2-Amino-6-MP
2-amino-6-Purinethiol
2-Amino-6-purinethiol
2-Amino-9H-purine-6-thiol
2-Aminopurin-6-thiol
2-Aminopurin-6-thiol [Czech]
2-Aminopurine-6(1H)-thione
2-Aminopurine-6-thiol
2-Thioguanine
5580-03-0
6 Thioguanine
6-mercapto-2-Aminopurine
6-Mercapto-2-aminopurine
6-Mercaptoguanine
6-TG
6-Thioguanine
6-Thioguanine (6-TG)
6-Thioguanine, Thioguanine
A4660_SIGMA
A4882_SIGMA
AC-11125
AC1MC379
AI3-26078
AKOS003389499
Anhydrous, thioguanine
BSPBio_001994
BW 5071
C07648
C5H7N5S
CCRIS 8997
CHEBI:136864
CHEMBL727
CID2723601
cMAP_000061
D013866
D08603
DB00352
DivK1c_000428
DX4
EINECS 205-827-2
FT-0083572
glaxo Wellcome brand OF thioguanine
Glaxo Wellcome Brand of Thioguanine
glaxo Wellcome brand OF tioguanine
Glaxo Wellcome Brand of Tioguanine
GlaxoSmithKline brand OF thioguanine
GlaxoSmithKline Brand of Thioguanine
GlaxoSmithKline brand OF tioguanine
GlaxoSmithKline Brand of Tioguanine
Guanine, thio- (VAN)
HMS1921E09
HMS2092M11
HMS501F10
HSDB 2504
I14-1541
IDI1_000428
KBio1_000428
KBio2_000715
KBio2_002476
KBio2_003283
|
KBio2_005044
KBio2_005851
KBio2_007612
KBio3_001494
KBio3_002954
KBioGR_001452
KBioGR_002476
KBioSS_000715
KBioSS_002483
Lanvis
Lanvis (TN)
LS-888
LT00455187
MLS001333131
MLS001333132
MolPort-000-929-106
MolPort-001-813-204
MolPort-003-984-174
NCGC00094792-01
NCGC00094792-02
NCGC00094792-03
NCI60_041643
NCIOpen2_004153
NINDS_000428
NSC 752
NSC752
NSC-752
purine antimetabolite: antimetabolite: inhibits nucleic acid replication
S1774_Selleck
SBB067147
SMP2_000326
SMR000857244
SPBio_000849
Spectrum_000235
SPECTRUM1500573
Spectrum2_000695
Spectrum3_000577
Spectrum4_000926
Spectrum5_001455
ST50298831
T0212
Tabloid
TG
ThG
THG
Thioguanin GSK
thioguanine
Thioguanine
Thioguanine [USAN:BAN]
Thioguanine anhydrous
Thioguanine hemihydrate
Thioguanine Hemihydrate
Thioguanine monosodium salt
Thioguanine Monosodium Salt
Thioguanine tabloid
Thioguanine Tabloid
Thioguanine, anhydrous
ThioguaninGSK
Thioguanin-GSK
Tioguanin
Tioguanina
Tioguanina [INN-Spanish]
Tioguanina wellcome
Tioguanina Wellcome
Tioguanine
Tioguanine (INN)
Tioguanine glaxosmithkline brand
Tioguanine GlaxoSmithKline Brand
Tioguaninum
Tioguaninum [INN-Latin]
UNII-FTK8U1GZNX
UNII-WIX31ZPX66
Wellcome brand OF thioguanine
Wellcome Brand of Thioguanine
Wellcome U3B
WLN: T56 BNM FYM INJ FUS HZ
ZINC18085533
|
|
| 7 |
|
Daunorubicin |
Approved |
Phase 3 |
|
20830-81-3 |
30323
|
|
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
Acetyladriamycin
AI3-52942
Anthracyline
Antibiotics from Streptomyces coeruleorubidus
Antibiotics From Streptomyces Coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
Cerubidin
Cerubidine
CHEBI:41977
CHEMBL178
CID30323
D07776
Daunamycin
Daunarubicinum
dauno Rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
daunorubicin
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
|
Daunorubicin [INN:BAN]
Daunorubicin Hcl
DAUNORUBICIN HCL
Daunorubicin hydrochloride
Daunorubicin Hydrochloride
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
dauno-Rubidomycine
Dauno-Rubidomycine
Daunoxome
DaunoXome
DaunoXome (TN)
DB00694
DM1
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
Hydrochloride, daunorubicin
Leukaemomycin C
LMPK13050002
LS-187381
LS-997
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NChemBio.2007.10-comp14
nchembio723-comp2
NCI-C04693
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
Rcra Waste No. U059
RCRA waste no. U059
RP 13057
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
|
|
| 8 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3,Not Applicable |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 9 |
|
Busulfan |
Approved, Investigational |
Phase 3,Phase 2 |
|
55-98-1 |
2478
|
|
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
glaxo Wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
| 10 |
|
Vidarabine |
Approved, Investigational |
Phase 3,Phase 2,Not Applicable |
|
24356-66-9 |
32326
21704
|
|
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-amino-PURIN-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9 beta Arabinofuranosyladenine
9 beta D Arabinofuranosyladenine
9-Arabinosyladenine
9-b-D-Arabinofuranosyl-9H-purin-6-amine
9-b-D-Arabinofuranosyladenine
9-beta-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
a, alpha-Ara
a, Ara
a, beta-Ara
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
adenine-D-ribose
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
adenosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
ADENOSINE, U.S.P.
Adenosine-8-14C
Adensoine
Ade-Rib
ADN
AI3-52413
AI3-52821
alpha Ara a
alpha D Arabinofuranosyladenine
alpha-Ara a
alpha-Ara A
alpha-D-Arabinofuranosyladenine
Ambap5536-17-4
AR-1H6029
Ara a
Ara A
Ara-a
Ara-A
ARA-A NSC 247519
Araadenosine
Ara-ATP
Arabinofuranosyladenine
Arabinoside adenine
Arabinoside, adenine
Arabinosyl adenine
Arabinosyladenine
Arabinosyl-adenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
beta Ara a
beta-Adenosine
beta-Ara a
beta-Ara A
beta-D-Adenosine
Bio1_000437
Bio1_000926
Bio1_001415
bmse000061
Boniton
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
C00212
CAS-5536-17-4
Caswell No. 010B
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
|
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
Lopac0_000123
LS-15059
LS-15085
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Monarch brand OF vidarabine
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC247519
NSC404241
NSC-404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
Pallacor
Parke davis brand OF vidarabine
PDSP1_001036
PDSP2_001020
Polyadenosine
Polyriboadenosine
Prestwick_983
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
Sandesin
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
Spectrum_001894
SPECTRUM1500107
SPECTRUM1500609
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spongoadenosine
SR 96225
SR-96225
STK361815
SUN-Y4001
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira a
Vira ATM
Vira-a
ViraA
Vira-A
Vira-A, Vidarabine
VIRDARABINE
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
|
|
| 11 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3,Phase 2 |
|
6055-19-2, 50-18-0 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 12 |
|
Fludarabine |
Approved |
Phase 3,Phase 2,Not Applicable |
|
75607-67-9, 21679-14-1 |
30751
|
|
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
21679-14-1
2-F-ara-A
2-F-ARAA
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-fluoro-ARA AMP
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
AC1LCW8I
AC1Q51CF
Beneflur
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
|
CPD000058874
D07966
EINECS 244-525-5
FAMP
FaraA
F-Ara-A
FaraAMP
F-Ara-AMP
Fludara
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine [INN]
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
fluoro-Ara-AMP
Fluradosa
Fluradosa (TN)
FT-0082766
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
|
|
| 13 |
|
Tacrolimus |
Approved, Investigational |
Phase 3,Phase 2 |
|
104987-11-3 |
445643
439492
|
|
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
| 14 |
|
Mycophenolic acid |
Approved |
Phase 3,Not Applicable |
|
24280-93-1 |
446541
|
|
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acid, mycophenolic
Acide mycophenolique
acido Micofenolico
Acido micofenolico
Acidum mycophenolicum
Melbex
|
micofenolico acido
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsaeure
Mycophenolsäure
Myfortic
|
|
| 15 |
|
Folic Acid |
Approved, Nutraceutical, Vet_approved |
Phase 3,Phase 2 |
|
59-30-3 |
6037
|
|
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
|
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
| 16 |
|
Antimetabolites |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 17 |
|
Immunologic Factors |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 18 |
|
Hydrocortisone-17-butyrate |
|
Phase 3 |
|
|
|
| 19 |
|
asparaginase |
|
Phase 3 |
|
|
|
|
Synonyms:
Elspar
L-asparagine amidohydrolase
|
Putative L-asparaginase precursor
|
|
| 20 |
|
Antirheumatic Agents |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 21 |
|
Anti-Infective Agents |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 22 |
|
Folic Acid Antagonists |
|
Phase 3,Phase 2 |
|
|
|
| 23 |
|
Vitamin B9 |
|
Phase 3,Phase 2 |
|
|
|
| 24 |
|
Vitamin B Complex |
|
Phase 3,Phase 2 |
|
|
|
| 25 |
|
Anti-Bacterial Agents |
|
Phase 3,Not Applicable |
|
|
|
| 26 |
|
Dermatologic Agents |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 27 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
| 28 |
|
Hydrocortisone 17-butyrate 21-propionate |
|
Phase 3 |
|
|
|
| 29 |
|
Topoisomerase Inhibitors |
|
Phase 3 |
|
|
|
| 30 |
|
Antiviral Agents |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 31 |
|
Folate |
|
Phase 3,Phase 2 |
|
|
|
| 32 |
|
Antimetabolites, Antineoplastic |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 33 |
|
Antibiotics, Antitubercular |
|
Phase 3,Not Applicable |
|
|
|
| 34 |
|
Nucleic Acid Synthesis Inhibitors |
|
Phase 3,Phase 2 |
|
|
|
| 35 |
|
Immunosuppressive Agents |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 36 |
|
Cortisol succinate |
|
Phase 3 |
|
|
|
| 37 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3,Phase 2 |
|
|
|
| 38 |
|
Cyclosporins |
|
Phase 3,Not Applicable |
|
|
|
| 39 |
|
Vidarabine Phosphate |
|
Phase 3,Not Applicable |
|
|
|
| 40 |
|
Alkylating Agents |
|
Phase 3,Phase 2 |
|
|
|
| 41 |
|
Antifungal Agents |
|
Phase 3,Not Applicable |
|
|
|
| 42 |
|
Antitubercular Agents |
|
Phase 3,Not Applicable |
|
|
|
| 43 |
|
Calcineurin Inhibitors |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 44 |
|
Promethazine |
Approved, Investigational |
Phase 2 |
|
60-87-7 |
4927
|
|
Synonyms:
(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
(2-dimethylamino-2-Methyl)ethyl-N-dibenzoparathiazine
(2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
(Dimethylamino-2-propyl-10-phenothiazine hydrochloride
10-(2-(Dimethylamino)-2-methylethyl)phenothiazine
10-(2-(Dimethylamino)propyl)phenothiazine
10-(2-Dimethylaminopropyl)phenothiazine
10-[2-(dimethylamino)Propyl]phenothiazine
10-[2-(Dimethylamino)propyl]phenothiazine
10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl- (9CI)
10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-, radical ion(1+)
3277 RP
3389 R.p.
38878-40-9
4182 R.p.
4-27-00-01253 (Beilstein Handbook Reference)
60-87-7
73745-50-3
A-91033
AB00053535
AC-15939
AC1L1J92
Antiallersin
Aprobit
Atosil
Avomine
BPBio1_000744
BRN 0088554
BSPBio_000676
BSPBio_002777
C07404
Camergan
CCRIS 7056
CHEBI:8461
CHEMBL643
CID4927
D00494
DB01069
Dimapp
Dimethylamino-isopropyl-phenthiazin
Dimethylamino-isopropyl-phenthiazin [German]
Diphergan
Diprazin
Diprazine
Diprozin
DivK1c_000005
EINECS 200-489-2
Fargan
Fenazil
Fenetazina
Fenetazine
Genphen
Hiberna
Histargan
HMS2089E08
HSDB 3173
Hydrochloride, promethazine
IDI1_000005
Iergigan
InChI=1/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
Isophenergan
Isopromethazine
KBio1_000005
KBio2_001348
KBio2_003916
KBio2_006484
KBio3_001997
KBioGR_001697
KBioSS_001348
L000495
Lercigan
Lergigan
Lilly 01516
Lilly 1516
Lopac0_000899
LS-264
Metaryl
MolPort-001-783-684
N-(2'-dimethylamino-2'-Methyl)ethylphenothiazine
N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine
N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,a-Trimethyl-10H-phenothiazine-10-ethanamine
N,N,α-trimethyl-10H-phenothiazine-10-ethanamine
N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
|
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine hydrochloride
NCGC00015817-10
NCGC00089735-02
NCGC00089735-03
NCI60_001878
NCI-C60673
N-Dimethylamino-2-methylethyl thiodiphenylamine
NINDS_000005
NSC 30321
NSC30321
Oprea1_758749
Pelpica
Phargan
Phenargan
Phenergan
Phenerzine
Phenoject-50
Phensedyl
Pilothia
Pilpophen
Pipolfen
Pipolphen
Pipolphene
Prestwick0_000888
Prestwick1_000888
Prestwick2_000888
Prestwick3_000888
Pro-50
Proazaimine
Proazamine
Procit
Promacot
Promazinamide
Promergan
Promesan
Promet
Prometasin
Prometazin
Prometazina
Prometazina [INN-Spanish]
Prometazine
Prometh
Promethacon
Promethaine
Promethazin
promethazine
Promethazine
Promethazine (JAN/INN)
PROMETHAZINE (SEE ALSO PROMETHAZINE HYDROCHLORIDE 58-33-3)
Promethazine [INN:BAN]
Promethazine hydrochloride
PromethazineHcl
Promethazinum
Promethazinum [INN-Latin]
Promethegan
Promethiazine
Promezathine
Prorex
Protazine
Prothazin
Prothazine
Provigan
Pyrethia
Pyrethiazine
Remsed
Romergan
RP 3277
Rumergan
SKF 1498
SPBio_000799
SPBio_002895
Spectrum_000868
Spectrum2_000840
Spectrum3_001019
Spectrum4_001149
Spectrum5_000977
Tanidil
Thiergan
UNII-FF28EJQ494
Valergine
Vallergine
WLN: T C666 BN ISJ B1Y1&N1&1
WY 509
Zipan-25
|
|
| 45 |
|
Mannitol |
Approved, Investigational |
Phase 2 |
|
69-65-8 |
453
6251
|
|
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
Dulcite
e 421
e421
e-421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
|
M9546_SIAL
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit P
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM no. 35
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
UNII-3OWL53L36A
ZINC02041302
|
|
| 46 |
|
Acetaminophen |
Approved |
Phase 2 |
|
103-90-2 |
1983
|
|
Synonyms:
4-(acetylamino)Phenol
4-(Acetylamino)phenol
4-acetamidophenol
4-Acetamidophenol
4-Acetaminophenol
4'-hydroxyacetanilide
4'-Hydroxyacetanilide
4-Hydroxyacetanilide
4-Hydroxyanilid kyseliny octove
A.F. anacin
Abenol
Abensanil
Abrol
Abrolet
AC1Q1KYJ
AC1Q1KYK
Acamol
Accu-tap
Accu-Tap
Acenol
Acephen
Acertol
Aceta elixir
Aceta Elixir
Aceta tablets
Aceta Tablets
Acetaco
Acetagesic
Acetalgin
Acetaminofen
Acetaminofén
Acetaminophen uniserts
Acetaminophene
Acétaminophène
Acetamol
Acetavance
Acetofen
Actamin
Actamin extra
Actamin super
Actifed plus
Actifed Plus
Actimol
Actimol chewable tablets
Actimol children's suspension
Actimol infants' suspension
Actimol junior strength caplets
Actron
Afebrin
Afebryl
Aferadol
Algesidal
Algina
Algomol
Algotropyl
Allay
alpha-Per
Alpiny
Alpinyl
Alvedon
Amadil
Aminofen
Aminofen max
Anacin
Anacin 3
Anacin-3
Anacin-3 extra strength
Anadin dla dzieci
Anaflon
Analter
Anapap
Andox
Anelix
Anexsia
Anexsia 10/660
Anexsia 5/325
Anexsia 7.5/325
Anexsia 7.5/650
Anhiba
Anoquan
Anti-algos
Antidol
Anuphen
Apacet
Apacet capsules
Apacet elixir
Apacet extra strength caplets
Apacet extra strength tablets
Apacet regular strength tablets
Apadon
Apamid
Apamide
APAP
a-Per
A-Per
Apitrelal
apo-Acetaminophen
Arfen
Arthralgen
Asetam
Asomal
Aspac
Aspirin free anacin maximum strength caplets
Aspirin free anacin maximum strength gel caplets
Aspirin free anacin maximum strength tablets
Aspirin-free anacin
Aspirin-free excedrin caplets
Asplin
Atasol
Atasol caplets
Atasol drops
Atasol forte caplets
Atasol forte tablets
Atasol oral solution
Atasol tablets
Atralidon
Babikan
Bacetamol
Bancap
Bancap HC
Banesin
Bayer Select
Bayer select allergy-sinus
Bayer select head cold
Bayer select headache pain
Bayer select maximum strength headache pain relief formula
Bayer select menstrual multi-symptom
Bayer select sinus pain relief
Benmyo
Ben-u-ron
Bickie-mol
Biocetamol
Bucet
Butalbital
Butapap
Cadafen
Calapol
Calmanticold
Calonal
Calpol
Capital
Capital with codeine
Captin
Causalon
CCRIS 3
Cefalex
Cetadol
CHEBI:46195
Children'S acetaminophen elixir drops
Children'S acetaminophen oral solution
Children'S tylenol chewable
Claradol codeine
Clixodyne
Codabrol
COD-Acamol forte
Codalgin
Codapane
Codicet
Codisal
Codisal forte
Codoliprane
Codral pain relief
Cofamol
Co-Gesic
CO-Gesic
Conacetol
Contac cough & sore throat formula
Contra-schmerz P
Coricidin
Coricidin D
Coricidin sinus
Cosutone
Croix blanche
Cuponol
Curadon
Curpol
Custodial
D oliprane
Dafalgan
Dapa
Dapa X-S
Darocet
Darvocet
Darvocet-N 50
Datril
Datril extra-strength
Daygrip
Demilets
Deminofen
Democyl
Demogripal
Desfebre
Dhamol
DHC Plus
Dial-a-gesic
Dial-alpha-gesic
Dimindol
Dirox
Disprol
Dolcor
Dolefin
Dolegrippin
Dolene ap-65
Dolene AP-65
Dolgesic
Doliprane
Dolko
Dolofugin
Doloreduct
Dolorfug
Dolorol forte
Dolorstop
Dolotec
Dolprone
Dol-stop
Dorocoff
Dresan
Dristan cold no drowsiness
Dristancito
Drixoral Plus
Duaneo
Dularin
Duorol
Duracetamol
Duradyne DHC
Durapan
Dymadon
Dymadon co
Dymadon Co
Dymadon forte
Dypap
Ecosetol
Elixodyne
Empracet
Endecon
Enelfa
Eneril
Esgic
Esgic-plus
Eu-med
Eu-Med
Excedrin
Excedrin caplets
Excedrin extra strength caplets
Excipain
Exdol
Exdol strong
Fanalgic
Farmadol
Febranine
Febrectal
Febrectol
Febrex
Febricet
Febridol
Febrilix
Febrin
Febrinol
febro-Gesic
Febro-Gesic
Febrolin
Femcet
Fendon
Fensum
Fepanil
Fever All
Feverall
Feverall junior strength
Feverall sprinkle caps junior strength
Fevor
Finimal
Finiweh
Fioricet
Fluparmol
Fortalidon P
Freka-cetamol
Gattaphen T
Gelocatil
Geluprane
Genapap
Genapap children's elixir
Genapap children's tablets
Genapap extra strength caplets
Genapap extra strength tablets
Genapap regular strength tablets
Genebs
Genebs extra strength caplets
Genebs regular strength tablets
Genebs X-tra
Geralgine-P
Gripin bebe
Gripin Bebe
Grippostad
Gynospasmine
Hedex
Helon N
Homoolan
Hycomine compound
Hydrocet
Hy-phen
Hy-Phen
Ildamol
Inalgex
Infadrops
Infants' feverall
Influbene N
Injectapap
Intensin
Janupap
Jin Gang
Junior disprol
Kataprin
KBio1_000660
Kinder finimal
Korum
Kratofin simplex
L024125
Labamol
Lekadol
Lemgrip
Lemsip
Lestemp
Liqiprine
Liquagesic
Liquigesic co
Liquiprin
Liquiprin children's elixir
Liquiprin infants" drops
Lonarid
Lonarid mono
Lonarid Mono
Lorcet-HD
Lortab
Lupocet
Lyteca
Lyteca syrup
Lyteca Syrup
Magnidol
Malex N
Malgis
Malidens
Maxadol
Medigesic plus
Medinol paediatric
Medocodene
Melabon infantil
Mexalen
Midol maximum strength
Midol PM night time formula
Midol regular strength
Midol teen formula
Migraleve yellow
Minafen
Minoset
Miralgin
|
Momentum
mono Praecimed
Multin
N-(4-Hydroxyphenyl)acetamide
N-Acetyl-4-aminophenol
N-acetyl-p-aminophenol
N-Acetyl-P-aminophenol
Naldegesic
NAPA
Napafen
Napap
Naprinol
NCX 701
Nealgyl
Nebs
NEBS
NeoCitran
Neodol
Neodolito
neo-Fepramol
Neo-Fepramol
Neopap
Neotrend
Neuridon
New cortal for children
NilnOcen
Nina
Nobedon
Nodolex
NO-Febril
Noral
Norcet
Norco
NSC3991
O-Acetaminophenol
Ofirmev
Oltyl
Oralgan
Oraphen-PD
Ortensan
Oxycet
Oxycocet
Oxycodone 2.5/apap 500
Oxycodone 5/apap 500
P-(acetylamino)Phenol
Paceco
Pacemo
Pacemol
Pacet
p-acetamidophenol
P-Acetamidophenol
p-acetaminophenol
P-Acetaminophenol
p-Acetylaminophenol
P-Acetylaminophenol
Pacimol
Paedialgon
Paedol
Painex
Paldesic
Pamol
Panacete
Panadeine
Panadeine co
Panadeine Co
Panadiene
panado-Co
Panado-Co
panado-co Caplets
Panadol
Panadol extra strength
Panadol junior strength caplets
Panadol maximum strength caplets
Panadol maximum strength tablets
Panale ve
Panaleve
Panamax
Panasorb
Panasorbe
Panets
Panex
Panodil
Panofen
Pantalgin
Papa-Deine
Papa-deine #3
Papa-deine #4
Paracemol
Paracenol
Paracet
Paracetamol
Paracétamol
Paracetamol al
Paracetamol antipanin P
Paracetamol basics
Paracetamol BC
Paracetamol DC
Paracetamol dr. schmidgall
Paracetamol fecofar
Paracetamol genericon
Paracetamol hanseler
Paracetamol harkley
Paracetamol heumann
Paracetamol hexal
Paracetamol italfarmaco
Paracetamol nycomed
Paracetamol PB
Paracetamol raffo
Paracetamol ratiopharm
Paracetamol rosch
Paracetamol saar
Paracetamol smithkline beecham
Paracetamol stada
Paracetamol von CT
Paracetamol winthrop
Paracetamole
Paracetamolo
Paracetamolum
Paracetanol
Paracetol
Paracin
Paracod
Paracodol
Parador
Paradrops
Parakapton
Parake
Paralen
Paralief
Paralink
Paralyoc
Paramol
Paramolan
Paranox
Parapan
Parasedol
Parasin
Paraspen
Para-suppo
Para-Suppo
Para-tabs
Parcetol
Parelan
Parmol
Parogal
Paroma
Pasolind
Pasolind N
PCM Paracetamol lichtenstein
Pediapirin
Pediatrix
Pedric
Percocet
Percocet-5
Percocet-demi
Percogesic with codeine
Perdolan mono
Perfalgan
Pe-tam
Pe-Tam
Phenaphen
Phenaphen caplets
Phenaphen Caplets
Phenaphen w/codeine
Phendon
Phenipirin
Phogoglandin
Phrenilin
Phrenilin forte
Phrenilin Forte
p-hydroxy-acetanilid
p-hydroxyacetanilide
P-Hydroxyacetanilide
p-hydroxyphenolacetamide
P-Hydroxyphenolacetamide
Pinex
Piramin
Pirinasol
Plicet
Polmofen
Predimol
Predualito
Prestwick_13
Prodol
Prompt
Prontina
Propacet
Propacet 100
Proval #3
Puernol
Pulmofen
Pyregesic-C
Pyrigesic
Pyrinazine
Pyromed
Quiet world
Redutemp
Reliv
Remedol
Rhinex D-lay tablets
Rivalgyl
Robigesic
Robitussin night relief
Rockamol plus
Rounox
Roxicet
Roxicet 5/500
Roxilox
RubieMol
Rubophen
Rupemol
Salzone
Sanicet
Sanicopyrine
Scanol
Scentalgyl
Scherzatabletten rezeptur 534
Schmerzex
Sedalito
Sedapap
Semolacin
Servigesic
Seskamol
Setakop
Setamol
Setol
Sifenol
Sinaspril
Sinedol
Sine-OFF sinus medicine caplets
Sinmol
Sinubid
SK-Apap
Snaplets-FR
Spalt fur die nacht
Spalt N
SPBio_002836
ST Joseph aspirin-free
ST Joseph aspirin-free for children
St. joseph cold tablets for children
St. joseph fever reducer
St. Joseph Fever Reducer
Stanback
Stopain
Sudafed severe cold formula
Sudafed sinus
Sunetheton
Supac
Supadol mono
Supofen
Suppap
Suppap-120
Suppap-325
Suppap-650
Supramol-m
Supramol-M
Synalgos-Dc-A
Synalgos-DC-a
Tabalgin
Tachiprina
Talacen
Tapanol
Tapanol extra strength caplets
Tapanol extra strength tablets
Tapar
Tavist allergy/sinus/headache
Tavist Allergy/Sinus/Headache
Tazamol
Temlo
Tempanal
Tempra
Tempra caplets
Tempra chewable tablets
Tempra d.s
Tempra drops
Tempra syrup
Tencon
Termacet
Termalgin
Termalgine
Termofren
TheraFlu
Tibinide
Tibizide
Tiffy
Tisin
Tisiodrazida
Titralgan
Tizide
Tocris-1706
Toximer P
Tralgon
Treupel mon
Treupel N
Treuphadol
Triad
Triaminic sore throat formula
Triaprin
Tricoton
Tussapap
Ty lenol
Tycolet
TYL
Tylenol
Tylenol (TN)
Tylenol allergy sinus
Tylenol arthritis extended relief
Tylenol caplets
Tylenol children's chewable tablets
Tylenol children's elixir
Tylenol children's suspension liquid
Tylenol drops
Tylenol elixir
Tylenol extra strength adult liquid pain reliever
Tylenol extra strength caplets
Tylenol extra strength gelcaps
Tylenol extra strength tablets
Tylenol gelcaps
Tylenol infants drops
Tylenol infants" suspension drops
Tylenol junior strength caplets
Tylenol junior strength chewable tablets
Tylenol regular strength caplets
Tylenol regular strength tablets
Tylenol tablets
Tylex
Tylex CD
Tylol
Tylox
Tylox-325
Tymol
Ultracet
Upsanol
Utragin
Valadol
Valgesic
Valorin
Valorin extra
Valorin Extra
Vanquish
Veralgina
Vermidon
Verpol
Viclor richet
Vicodin
Vicodin es
Vicodin HP
Vips
Viruflu
Vivimed
Volpan
Wygesic
Zatinol
Zolben
|
|
| 47 |
|
Diphenhydramine |
Approved, Investigational |
Phase 2 |
|
147-24-0, 58-73-1 |
3100
|
|
Synonyms:
147-24-0
147-24-0 (HYDROCHLORIDE)
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride
2-(diphenylmethoxy)-N,N-dimethylethanamine
2-(Diphenylmethoxy)-N,N-dimethylethylamine
2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine
2-benzhydryloxyethyl-N,N-dimethylammonium
2-benzhydryloxy-N,N-dimethylethanamine
2-diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-demthylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
2PM
58-73-1
88637-37-0 (citrate (1:1))
a-(2-Dimethylaminoethoxy)diphenylmethane
AB00053460
AC-13704
AC1L1F65
AKOS003658554
Aleryl
Alledryl
Allerdryl
Allergan
Allergan B
Allergeval
Allergical
Allergina
Allergival
Allermax Caplets
Aller-Med
alpha-(2-Dimethylaminoethoxy)diphenylmethane
Amidryl
Antistominum
Antitussive
Antomin
Automin
Bagodryl
Banophen
Banophen Caplets
Baramine
b-Dimethylaminoethanol diphenylmethyl ether
b-Dimethylaminoethyl benzhydryl ether
Beldin
Belix
Bena
Benachlor
Benadrin
Benadryl
Benadryl (hydrochloride)
Benadryl Allergy
BENADRYL HCl
Ben-allergin
Benapon
Bendylate
Benhydramin
Benodin
Benodine
Benylan
Benylin
Benzantin
Benzantine
Benzhydramine
Benzhydraminum
Benzhydril
Benzhydroamina
Benzhydryl
beta-Dimethylamino-aethyl-benzhydryl-aether
beta-Dimethylamino-aethyl-benzhydryl-aether [German]
beta-Dimethylaminoethanol diphenylmethyl ether
beta-dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethylbenzhydrylether
Betramin
BIDD:GT0152
BPBio1_000275
BRD-K47278471-003-05-7
BRN 1914136
BSPBio_000249
BSPBio_002219
CAS-147-24-0
CCRIS 1959
CHEBI:127629
CHEBI:4636
CHEMBL657
CID3100
Citrate, diphenhydramine
Compoz
CPD-10890
D00300
Dabylen
DB01075
DB06975
Debendrin
Dermistina
Dermodrin
Desentol
Diabenyl
Diabylen
Dibendrin
Dibenil
Dibondrin
Difedryl
Difenhidramina
Difenhidramina [INN-Spanish]
Difenhydramin
Difenhydramine
Difenidramina
Difenidramina [Italian]
Dihidral
Dimedrol
Dimedrol base
Dimedrolum
Dimedryl
|
Dimehydrinate
Dimethylamine benzhydryl ester
Diphamine
Diphantine
Diphen
Diphen Cough
Diphenhist
Diphenhist Captabs
diphenhydramine
Diphenhydramine (JP15/INN)
Diphenhydramine [INN:BAN:JAN]
Diphenhydramine Base
Diphenhydramine citrate
Diphenhydramine citrate (1:1)
Diphenhydramine HCl
Diphenhydramine hydrochloride
DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE
Diphenhydraminum
Diphenhydraminum [INN-Latin]
Diphenylhydramin
Diphenylhydramine
DivK1c_000368
Dobacen
Dormarex 2
Dormin
Dryistan
Drylistan
Dylamon
EINECS 200-396-7
Etanautine
FAR 90X2
Genahist
Histaxin
HMS2089E06
HSDB 3066
Hyadrine
Hydramine
Hydrochloride, diphenhydramine
Hyrexin
I14-6749
Ibiodral
IDI1_000368
KBio1_000368
KBio2_001460
KBio2_004028
KBio2_006596
KBio3_001439
KBioGR_001099
KBioSS_001460
L000227
Lopac0_000377
Lopac-D-3630
LS-68208
Medidryl
Mephadryl
MLS002222276
MolPort-001-783-508
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
N-(Benzhydryloksy-etylo)dwumetyloamina
N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]
N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride
N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE
Nausen
NCGC00015335-01
NCGC00015335-02
NCGC00015335-03
NCGC00015335-10
NCGC00024414-03
NCGC00024414-04
nchembio747-comp18
NCI60_002916
NCI60_022782
Nervine Nighttime Sleep-Aid
NINDS_000368
Novamina
NSC665800
Nytol Quickcaps
Nytol Quickgels
O-benzhydryldimethylaminoethanol
O-Benzhydryldimethylaminoethanol
Oprea1_254625
PM 255
Prestwick0_000065
Prestwick1_000065
Prestwick2_000065
Prestwick3_000065
Probedryl
Restamin
Restamin (TN)
Rigidil
S51
Siladryl
Silphen
Sleep-Eze D
Sleep-Eze D Extra Strength
SMR001307259
SPBio_000961
SPBio_002170
Spectrum_000980
Spectrum2_000961
Spectrum3_000400
Spectrum4_000520
Spectrum5_000915
STK103720
STOCK2S-94461
Syntedril
Syntodril
TL8003758
Twilite Caplets
UNII-8GTS82S83M
Unisom Sleepgels Maximum Strength
α-(2-dimethylaminoethoxy)diphenylmethane
β-dimethylaminoethanol diphenylmethyl ether
β-dimethylaminoethyl benzhydryl ether
|
|
| 48 |
|
Benzyl alcohol |
Approved |
Phase 2 |
|
100-51-6 |
244
|
|
Synonyms:
(Hydroxymethyl)benzene
.alpha.-hydroxytoluene
.alpha.-toluenol
a-Hydroxytoluene
Alcohol, benzyl
Alcoholum benzylicum
Alcool benzylique
Alcoolbenzylique
alpha-Hydroxytoluene
alpha-Toluenol
Aromatic alcohol
Aromatic primary alcohol
a-Toluenol
Bentalol
Benzal alcohol
Benzalalcohol
Benzalcohol
Benzenecarbinol
Benzenemethanol
Benzenmethanol
Benzoyl alcohol
Benzyl alcohol
Benzyl alkohol
|
Benzyl-alcohol
BenzylAlcohol
Benzylalkohol
Benzylic alcohol
Benzylicum
Caswell no. 081F
Enzylalcohol
Euxyl K 100
Hydroxymethylbenzene
Hydroxytoluene
Itch-X
MBN
Methanol benzene
Phenolcarbinol
Phenylcarbinol
Phenylcarbinolum
Phenylmethanol
Phenylmethyl alcohol
Sunmorl BK 20
TB 13g
α-hydroxytoluene
α-toluenol
|
|
| 49 |
|
Ethanol |
Approved |
Phase 2 |
|
64-17-5 |
702
|
|
Synonyms:
(C6-C9)Alkyl alcohol
[CH2Me(OH)]
[OEtH]
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
1-Hydroxyethane
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
absolute alcohol
Absolute alcohol
Absolute Alcohol
Absolute ethanol
Absolute Ethanol
Absolute ethyl alcohol
AC1L19TW
AC1Q31MM
Aethanol
Aethanol [German]
Aethylalkohol
AHD 2000
AI3-01706
Alcare hand degermer
Alcare Hand Degermer
alcohol
Alcohol
Alcohol (ethyl)
Alcohol (USP)
Alcohol [USP]
ALCOHOL 5% IN D5-W
Alcohol anhydrous
Alcohol Anhydrous
Alcohol dehydrated
Alcohol denatured
alcohol etilico
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Absolute
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, Dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, Diluted
Alcohol, ethyl
Alcohol, grain
Alcohol, Grain
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool ethylique
Alcool Ethylique
Alcool éthylique
Alcool etilico
Alcool Etilico
Algrain
Alkohol
Alkohol [German]
Alkoholu etylowego
Alkoholu Etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
bmse000297
C00469
C2H5OH
C2H6O
Caswell No. 426
Caswell No. 430
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
|
CHEMBL545
CID702
Colamine
Cologne spirit
Cologne Spirit
Cologne spirits
D000431
D00068
DB00898
Dehydrated alcohol
Dehydrated ethanol
Dehydrated Ethanol
Denatured alcohol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Denatured Ethanol
Desinfektol el
Desinfektol EL
Diluted alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
Envision Conditioner Pdd 9020
EOH
EOX
Esumiru WK 88
ETA
etanol
Etanol
Etanolo
Etanolo [Italian]
ethanol
éthanol
Ethanol (9CI)
Ethanol [JAN]
Ethanol 200 proof
Ethanol 200 Proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol Vapor
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl alc
ethyl alcohol
Ethyl alcohol
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl Alcohol Anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl Hydrate
Ethyl hydroxide
Ethyl Hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
EtOH
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
grain alcohol
Grain alcohol
Hinetoless
HSDB 531
HSDB 82
Hydroxyethane
HYDROXYETHYL GROUP
I14-12648
IMS 99
Infinity pure
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated spirit
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
MolPort-001-785-844
NCGC00091458-01
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
potato Alcohol
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spirits OF wine
spiritus vini
Spiritus vini
Spirt
SY Fresh M
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
UNII-3K9958V90M
USAF EK-1597
WLN: Q2
|
|
| 50 |
|
Antilymphocyte Serum |
|
Phase 2 |
|
|
|
Interventional clinical trials:
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome |
Completed |
NCT00003593
|
Phase 3 |
asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine |
| 2 |
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia |
Completed |
NCT00322101
|
Phase 3 |
cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate |
| 3 |
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder |
Withdrawn |
NCT00411281
|
Phase 3 |
cytarabine |
| 4 |
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer |
Completed |
NCT00787761
|
Phase 2 |
busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus |
| 5 |
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
Completed |
NCT01231919
|
Phase 1 |
Akt inhibitor MK2206 |
| 6 |
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease |
Completed |
NCT01164163
|
Phase 1 |
ruxolitinib phosphate |
| 7 |
Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder |
Completed |
NCT01511575
|
|
|
| 8 |
Study of Blood Samples From Newborns With Down Syndrome |
Active, not recruiting |
NCT00959283
|
|
|
| 9 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
Active, not recruiting |
NCT00014235
|
Not Applicable |
fludarabine phosphate;cyclosporine;mycophenolate mofetil |
|
